Navigation Links
Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
Date:4/27/2009

Next Safety, Inc. has developed the most effective pulmonary nicotine delivery device to help people quit smoking

JEFFERSON, N.C., April 27 /PRNewswire/ -- Matthew P. Bars, MS, CTTS, has joined Next Safety, Inc. (NSI) as chairman. In his smoking cessation work, he has appeared on the NBC Today Show several times, as well as the CBS Evening News with Dan Rather, ABC World News Tonight, CNBC and CNN.

Mr. Bars has a B.S. in Psychology, an M.S. in Clinical Psychology and is a member of the American Academy of Addiction Psychiatry. He is a consultant and key opinion-maker for many pharmaceutical, healthcare, and medical diagnostic companies and has been engaged in the treatment, management, and administration of nicotine addiction services since 1980.

Mr. Bars is a contributing editor to the National Cancer Institute's "Clearing the Air" stop-smoking publication. He is also the expert consultant and director for smoking cessation for the Fire Department of New York City and the co-developer of the "Tobacco Free with the New York FD" program. He is the current clinical director of the Palisades Medical Center's IQuit Smoking Program (an affiliate of the Columbia University New York Presbyterian Healthcare System and a director of the IQuit Smoking Consultation Service).

"I have worked against nicotine addiction for almost 30 years and I am excited to be working with a company that is poised to save lives with what I have named 'the Next Step' in nicotine replacement therapy," said Mr. Bars.

In human trials, utilizing the Next Safety Platform, the device was highly effective in the pulmonary delivery of nicotine and other drugs. The phase I trials included blood results that were independently measured by a leading laboratory at a major academic research institution. Participants reported significant psychoactive effects.

NSI's proprietary platform is a powerful new method for the pulmonary delivery of drugs; the small handheld device will allow the user to inhale nicotine vapor and other drugs from an air stream with a high degree of control and safety. The company's manufacturing partners for the production of its nicotine delivery device are large global companies with more than 150 combined international sites, including a number of FDA-approved manufacturing facilities in the US.

NSI has an agreement with a major US-based pharmaceutical company to supply pharmaceutical-grade nicotine. NSI expects the price of an equivalent amount of nicotine delivered by its device, as compared to the amount of nicotine delivered by a carton of cigarettes, to be less than 10% of the current average market price in the US.

In addition, NSI is testing other drugs that use its new pulmonary drug delivery platform for a number of leading pharmaceutical companies. These drugs include treatments for asthma, pulmonary infections, and the delivery of proteins to treat certain types of cancer as well as insulin and proteins for treating other conditions.

    Contact:

    Eric Hunter
    336-246-7700

http://www.nextsafety.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Next Safety, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Akaza Research to Present OpenClinica at ACRP Global Conference & Exhibition
2. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
3. Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective
4. TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009
5. DuPont Leader: Agriculture is Up to Global Productivity Challenge
6. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
7. Global Aviation Summit Explores Low-Carbon Flight
8. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
9. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
10. Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
11. 3rd Global Jatrophaworld Training 2009... Set to Create and Build a Sustainable non-food Biodiesel Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):